Compare HUBG & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUBG | IMNM |
|---|---|---|
| Founded | 1971 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 1996 | 2020 |
| Metric | HUBG | IMNM |
|---|---|---|
| Price | $44.09 | $23.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $42.83 | $32.80 |
| AVG Volume (30 Days) | 586.7K | ★ 1.0M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $3,946,390,000.00 | $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.88 | $1,127.34 |
| P/E Ratio | $32.65 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.75 | $7.15 |
| 52 Week High | $53.26 | $27.65 |
| Indicator | HUBG | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 70.84 | 57.72 |
| Support Level | $33.71 | $19.23 |
| Resistance Level | $44.13 | $25.10 |
| Average True Range (ATR) | 1.57 | 1.02 |
| MACD | 0.47 | 0.05 |
| Stochastic Oscillator | 83.08 | 63.51 |
Hub Group ranks among the largest providers of rail intermodal service. Roughly 60% of consolidated revenue comes from Hub's intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload shipping unit. Hub's logistics segment includes its asset-light truck brokerage operations along with its outsourced transportation management, warehousing and fulfillment, and heavy-goods final mile delivery offerings. Hub often makes tuck-in acquisitions that expand its brokerage, last-mile, and dedicated offerings.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.